Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Assets (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Assets for 11 consecutive years, with $8.2 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 38.3% to $8.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.2 billion through Dec 2025, up 38.3% year-over-year, with the annual reading at $8.2 billion for FY2025, 38.3% up from the prior year.
  • Assets for Q4 2025 was $8.2 billion at BeOne Medicines, up from $7.6 billion in the prior quarter.
  • The five-year high for Assets was $8.5 billion in Q4 2021, with the low at $5.3 billion in Q3 2021.
  • Average Assets over 5 years is $6.3 billion, with a median of $5.8 billion recorded in 2024.
  • The sharpest move saw Assets soared 52.4% in 2021, then tumbled 35.78% in 2022.
  • Over 5 years, Assets stood at $8.5 billion in 2021, then tumbled by 35.78% to $5.5 billion in 2022, then rose by 5.91% to $5.8 billion in 2023, then grew by 1.99% to $5.9 billion in 2024, then skyrocketed by 38.3% to $8.2 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $8.2 billion, $7.6 billion, and $6.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.